320778-89-0

Upstream product

• 320778-87-8 (3aR,7aR)-2-methyl-3a,4,5,6,7,7a-hexahydro-1H-benz[d]imidazole 
• 20439-47-8 (1R,2R)-1,2-diaminocyclohexane 
• 1000-84-6 O-ethyl acetimidate 
• 2208-07-3 ethyl acetimidate hydrochloride 
• 438588-60-4 2-((1R,2R)-2-aminocyclohexyl)isoindoline-1,3-dione 
• 32044-22-7 (1R,2R)-1,2-diaminocyclohexane tartrate 

Downstream Products

• 34218-57-0 (R,R)-trans-N-[2-(N',N'-dimethylamino)hexyl]acetamide 
• 320778-91-4 N-[2-(5,7-dihydro-dibenzo[c,e]azepin-6-yl)-cyclohexyl]-acetamide 
• 943240-12-8 C₁₄H₁₉N₃O₅S 
• 824938-91-2 N-[((1R,2R)-2-piperidin-1-yl)-cyclohexyl]acetamide 
• 885677-91-8 (1R,2R)-N¹-piperidinyl-1,2-diaminocyclohexane 
• 1414942-52-1 N,N'-bis((R,R)-2-diethylaminocyclohexyl)oxalylamide 
• 1414942-51-0 (S)-N-((1R,2R)-2-diethylaminocyclohexyl)-4-methyl-2-(4-methylphenylsulfonamino)pentanamide 
• 1414942-50-9 3,5-di-tert-butyl-N-((1R,2R)-2-diethylaminocyclohexyl)-2-hydroxybenzamide 
• 1414942-49-6 N-((1R,2R)-2-diethylaminocyclohexyl)-2-ethoxybenzamide 
• 1414942-48-5 N-((1R,2R)-2-diethylaminocyclohexyl)-2-hydroxybenzamide 
• 1134192-83-8 1S,2S-N-benzyl-N'-(2-acetamidocyclohexyl)sulfamide 
• 67579-84-4 (1R,2R)-N₁,N₁-diethylcyclohexane-1,2-diamine 

Relevant academic research and scientific papers

Synthesis of Chiral Triazole-Based Halogen Bond Donors

The number of applications that use halogen bonding in the fields of self-assembly, supramolecular aggregation, and catalysis is growing. However, the accessibility of chiral halotriazoles shows that there is still a lot more to explore. The simple click-chemistry is applied for the straightforward synthesis of enantiomerically pure mono- and bidentate as well as multifunctional iodotriazole-based XB donors. The methodology is characterized by a wide variability due to easy access of chiral azides.

Investigations towards the stereoselective organocatalyzed Michael addition of dimethyl malonate to a racemic nitroalkene: Possible route to the 4-methylpregabalin core structure

Chiral derivatives of γ-aminobutyric acid are widely used as medicines and can be obtained by organocatalytic Michael additions. We show here the stereoselective synthesis of 4-methylpregabalin stereoisomers using a Michael addition of dimethyl malonate to a racemic nitroalkene. The key step of the synthesis operates as a kinetic resolution with a chiral squaramide catalyst. Furthermore, specific organocatalysts can provide respective stereoisomers of the key Michael adduct in up to 99:1 er.

Enantioselective Michael addition of 1,3-dicarbonyl compounds to a nitroalkene catalyzed by chiral squaramides-a key step in the synthesis of pregabalin

Asymmetric organocatalytic 1,4-additions provide access to a large number of biologically relevant compounds. Chiral squaramides efficiently catalyse enantioselective Michael addition of 1,3-dicarbonyl compounds to aliphatic nitroalkenes. The resulting γ-

IRON CATALYSTS WITH UNSYMMETRICAL PNN'P LIGANDS

The present invention relates to catalytic materials for hydrogenation or asymmetric hydrogenation. In particular, the invention relates to iron (II) complexes containing unsymmetrical tetradentate diphosphine (PNN'P) ligands with two different nitrogen donor groups useful for catalytic transfer hydrogenation or asymmetric transfer hydrogenation of ketones, aldehydes and imines.

New bifunctional organocatalysts based on (R,R)-cyclohexane-1,2-diamine for the asymmetric addition of nucleophiles to aldehydes

The amide and sulfamide derivatives of (1R,2R)-N,N-diethylcyclohexane-1,2- diamine can serve as organocatalysts for addition of Me3SiCN and Et2Zn to aldehydes.

PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein Ar is a group of formula (III), and R1, R2, R13, A, K, M, L1, L2, X, Y1, Y2, Q, salt thereof, wherein R1, R2, R13, A, K, L1, L2, W, X, Z1, Z2, Y1, Y2, Z1, Z2, M, Q, W, X, m, p and q are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

An efficient method for the preparation of N,N-disubstituted 1,2-diamines

C2-Symmetric 1,2-diamines are useful precursors to numerous reagents used in asymmetric synthesis and catalysis. We report here an efficient protocol for converting the two most commonly used trans-1,2-diamines to N,N-disubstituted derivatives, a transformation that simplifies the preparation of non-C2-symmetric diamines. Central to the method is the high-yielding conversion of the diamines to the corresponding monoacetylated derivatives via imidazoline intermediates. (C) 2000 Published by Elsevier Science Ltd.